A platelet activating factor receptor antagonist prevents the development of chronic arthritis in mice

Journal of Rheumatology

Volumn 26, Issue 5, 1999, Pages 1080-1086

  Palacios, Itziar ^a   Miguélez, Roberto ^a   Sánchez Pernaute, Olga ^a   Gutierrez, Sylvia ^a   Egido, Jesús ^a   Herrero Beaumont, Gabriel ^a,b  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b Division of Rheumatology   (Spain)

Author keywords

Arthritis; Fibronectin; Platelet activating factor; Proteoglycans

Indexed keywords

6 (2 CHLOROPHENYL) 4,7,8,10 TETRAHYDRO 9 (4 METHOXYPHENYLCARBAMOYL) 1 METHYLPYRIDO[4',3':4,5]THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE; COLLAGEN; FIBRONECTIN; PROTEOGLYCAN; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC ARTHRITIS; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; FEMALE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SYNOVIUM;

ANIMALS; ARTHRITIS, RHEUMATOID; AZEPINES; COLLAGEN; DISEASE MODELS, ANIMAL; FEMALE; FIBRONECTINS; IMMUNOHISTOCHEMISTRY; JOINTS; MICE; MICE, INBRED DBA; PLATELET AGGREGATION INHIBITORS; PLATELET MEMBRANE GLYCOPROTEINS; RECEPTORS, CELL SURFACE; RECEPTORS, G-PROTEIN-COUPLED; TRIAZOLES;

EID: 0032952436     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Kasama T, Strieter RM, Lukacs NW, Lincoln PM, Burdick MD, Kunkel SL. Interleukin 10 expression and chemokine regulation during the evolution of murine type II collagen-induced arthritis. J Clin Invest 1995;95:2868-76.
2. Courtenay JS, Dallman MJ, Dayan AD, Martin A, Mosedale B. Immunization against heterologous type II collagen induces arthritis in mice. Nature 1980;283:666-8.
3. Homandberg GA, Meyers R, Xie DL. Fibronectin fragments cause chondrolysis of bovine articular cartilage slices in culture. J Biol Chem 1992;267:3597-604.
4. Shiozawa S, Yoshihara R, Kuroki Y, Fujita T, Shiozawa K, Imura S. Pathogenic importance of fibronectin in the superficial region of articular cartilage as a local factor for the induction of pannus extension on rheumatoid articular cartilage. Ann Rheum Dis 1992;51:869-73.
5. Hynes RO. Fibronectins. New York: Springer Verlag Inc.; 1990.
6. López-Armada MJ, González E, Gómez-Guerrero C, Egido J. The 80 kD fibronectin increases the production of fibronectin and tumor necrosis factor-α in cultured mesangial cells. Clin Exp Immunol 1997;107:398-403.
7. Braquet P, Rola-Pleszczynski M. Platelet-activating factor and cellular immune responses. Immunol Today 1987;8:345-52.
8. Herrero-Beaumont G, Egido J. PAF, a potent proinflammatory mediator, looking for its role in the pathogenesis of joint damage. Ann Rheum Dis 1997;56:211-3.
9. Pinkard RN, Ludwig JL, McManus LM. Platelet activating factor. In: Gallin JI, Goldstein IM, Snyderman R, editors. Inflammation: basic principles and clinical correlates. New York: Raven Press; 1988.
10. Bazan NG. A signal terminator. Nature 1995;374:501-2.
11. Maestre C, Zarco P, Egido J, et al. Possible role of platelet activating factor in experimental and human arthritis: studies with PAF receptor antagonist. In: Braquet P, editor. Ginkgolides - Chemistry, biology, Pharmacology, and Clinical Perspectives. Barcelona: JR Prous Science Publishers; 1989.Vol 2.
12. Zarco P, Maestre C, Herrero-Beaumont G, Gonzalez E, Egido J. Involvement of platelet-activating factor and tumor necrosis factor in the pathogenesis of joint in rabbits. Clin Exp Immunol 1992;88:318-23.
13. Hilliquin P, Menkes CJ, Laoussadi S, Benveniste J, Arnoux B. Presence of PAF-acether in rheumatic diseases. Ann Rheum Dis 1992;51:29-31.
14. Gutierrez S, Palacios I, Egido J, et al. IL-1 and IL-6 stimulate the production of platelet activating factor (PAF) by cultured rabbit synovial cells. Clin Exp Immunol 1995;99:364-8.
15. Willians RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992;89:9784-8.
16. Joosten LAB, Helsen MMA, van de Loo FAJ, van der Berg WB. Anticytokine treatment of established type II collagen arthritis in DBA/1 mice. Arthritis Rheum 1996;39:797-809.
17. Camussi G. Interactive effects of tumour necrosis factor and platelet-activating factor in the pathogenesis of glomerular injury. Lab Invest 1994;70:435-6.
18. Hilliquin P, Natour J, Aissa J, et al. Treatment of carrageenaninduced arthritis by the platelet activating factor antagonist BN 50730. Ann Rheum Dis 1995;54:140-3.
19. Miguélez R, Palacios I, Navarro F, et al. Antiinflammatory effect of PAF receptor antagonist and a new molecule with antiproteinase activity in an experimental model of acute urate crystal arthritis. J Lipid Mediators 1996;13:35-49.
20. Bazan HE, Tao Y, Bazan NG. Platelet activating factor induces collagenase expression in corneal epithelial cells. Proc Natl Acad Sci USA 1993;90:8678-82.
21. Braquet P, Esanu A. New trends in PAF antagonist research: a new series of potent hetrazepine-derived PAF antagonist. Agents Actions 1991;32:34-6.
22. Girault J, Mlagouyat JM, Longueville D, Lecomte G, Revaud M, Fourtillan JB. Quantitative measurement of a new synthetic hetrazepine derivative, BN 50730, in human plasma and urine by combined liquid chromatography-negative chemical ionization mass spectrometry using a particle beam interface. J Chromatogr B Biomed Appl 1994;658:289-301.
23. Joosten LAB, Helsen MMA, van der Berg WB. Accelerated onset of collagen-induced arthritis by remote inflammation. Clin Exp Immunol 1994;97:204-11.
24. Caccese RI, Zimmerman JL, Carlson RP. Bacterial lipopolysaccharide potentiates type II collagen-induced arthritis in mice. Mediators Inflamm 1992;1:273-9.
25. Rosenberg L. Chemical basis for the histological use of safranin 0 in the study of articular cartilage. J Bone Joint Surg US 1971;53:69-82.
26. Cutolo M, Picasso M, Ponassi M, Zhen Sun M, Balza E. Tenascin and fibronectin distribution in human normal and pathological synovium. J Rheumatol 1992;19:1439-47.
27. Linck G, Stocker S, Grimaud JA, Porte A. Distribution of immunoreactive fibronectin and collagen (type I, QI, IV) in mouse joints: fibronectin, an essential component of the synovial cavity border. Histochemistry 1983;77:323-8.
28. Joosten LAB, Lubberts E, Duerz P, et al. Role of interleukin 4 and interleukin 10 in murine collagen-induced arthritis. Arthritis Rheum 1997;40:249-60.
29. Pignol B, Henane S, Sorlin B, Rola Pleszczynski M, Mencia-Huerta JM, Braquet P. Effect of long-term treatment with platelet-activating factor on IL-I and IL-2 production by rat spleen cells. J Immunol 1990;145:980-4.
30. Bazan NG, Hetcher BS, Herschamn HR, Mukherjee PK. Platelet activating factor and retinoic acid synergisticalty activate the inducible prostaglandin synthase gene. Proc Natl Acad Sci USA 1994;91:5252-6.
31. Thivierge M, Rola-Pleszcynski M. Up-regulation of inducible cyclooxygenase gene expression by platelet-activating factor in activated rat alveolar macrophages. J Immunol 1995;154:6593-9.
32. Kowanko IC, Bates EJ, Ferrante A. Platelet-activating factor inhibits proteoglycan synthesis and enhances neutrophil-mediated proteoglycan degradation in cartilage explants. Arthritis Rheum 1992;35:918-25.
33. Zheng ZG, Wood DA, Sims SM, Dixom SJ. Platelet activating factor stimulates resorption by rabbit osteoclasts in vitro. Am J Physiol 1993;264:E74-81.
34. Kashihara N, Watanabe Y, Makino H. Selective decreased de novo synthesis of glomerular proteoglycans under the influence of reactive oxygen species. Proc Natl Acad Sci USA 1992;89:6309-13.
35. Sanchez-Pernaute O, López-Armada MJ, Hernández P, et al. Antifibroproliferative effect of tenidap in chronic antigen-induced arthritis. Arthritis Rheum 1997;40:2147-56.
36. Ruiz-Ortega M, Largo R, Bustos C, Gomez-Garre D, Egido J. Platelet activating factor stimulates gene expression and synthesis of extracellular matrix proteins in cultured rat and human mesangial cells. Role of TGFβ. J Am Soc Nephrol 1997;8:1266-75.
37. Ruiz-Ortega M, Bustos C, Plaza JJ, Egido J. Overexpression of extracellular matrix proteins in renal tubulointerstitial cells by platelet activating factor stimulation. Nephrol Dial Transplant 1998;13:886-92.
38. Hilliquin P, Guinot P, Chermat-Izard V, Puechal X, Menkes CJ. Treatment of rheumatoid arthritis with platelet activating factor antagonist BN 50730. J Rheumatol 1995;22:1651-4.
39. Hilliquin P, Chermat-Izard V, Menkes CJ. A double blind placebo controlled study of a platelet activating factor antagonist in patients with rheumatoid arthritis. J Rheumatol 1998;25:1502-7.
40. Tjoelker LW, Wilder C, Eberhart C, et al. Anti-inflammatory properties of platelet activating factor acetylhydrolase. Nature 1995;374:549-52.